UNION therapeutics further strengthens management team with medical and business development profiles
Dr. Per Cantor, MD, DMSci, appointed as new Chief Medical Officer Mr. Eckhard Niemeier appointed as Chief Business Officer Mr. Mads Jellingsø promoted to Chief Commercial Officer Hellerup, Denmark, 31 […]
UNION therapeutics’ COVID-19 candidates found to be well tolerated in Phase 1 Lancet publication
The Lancet Regional Health – Europe has published the results of UNION therapeutics’ phase 1 study of inhaled and intranasal niclosamide products (UNI91103 and UNI91104) The study endpoints were to […]
The PROTECT-V trial investigating UNIONs COVID-19 candidate receives Urgent Public Health Prioritization from the UK government
Hellerup, Denmark, March 29, 2021 – UNION therapeutics A/S (UNION) today announced that the National Institute for Health Research (NIHR) in the UK has granted Urgent Public Health (UPH) prioritization to […]
The PROTECT-V trial investigating UNIONs COVID-19 candidate receives Urgent Public Health Prioritization from the UK government
Hellerup, Denmark, March 29, 2021 – UNION therapeutics A/S (UNION) today announced that the National Institute for Health Research (NIHR) in the UK has granted Urgent Public Health (UPH) prioritization to […]
UNION’s nasal spray for COVID-19 enters a 1,500 high-risk patient study
UNI91103 is a nasal spray delivering niclosamide – a potent inhibitor of SARS-CoV-2 with in-vitro potency >40x higher than remdesivir – to the nasal cavity UNI91103 has been selected as […]
UNION Completes Over-subscribed 155m DKK Equity Capital Raise to Accelerate Clinical Programs
Hellerup, Denmark, February 9, 2021 – UNION therapeutics A/S (“UNION”), a privately held, clinical stage pharmaceutical company, today announced the completion of a 155m DKK financing round from a group […]
UNION therapeutics A/S receives FDA approval for IND of oral next generation PDE4-inhibitor (orismilast) for investigation in plaque psoriasis
Orismilast is a next generation oral PDE4-inhibitor with an improved therapeutic window compared to other PDE4-inhibitors Oral orismilast (UNI50001) has demonstrated proof of concept in patients living with plaque psoriasis […]
UNION therapeutics appoints Dr. Kim Kjoeller as Chief Executive Officer and further strengthens leadership by appointing Dr. Günter Ditzinger as Chief Technology Officer
UNION strengthens leadership following expansion of clinical pipeline from one to five later stage clinical candidates during 2020 Dr. Kim Domela Kjoeller, Executive Vice President Global Research & Development at […]
Danish biotech UNION adds program to prevent COVID-19 with intranasal delivery of niclosamide.
· Niclosamide is a potent inhibitor of SARS-CoV-2 with potency >40x higher than remdesivir as demonstrated by Institut Pasteur Korea
· The sinonasal cavity is considered a major site of early infection by SARS-CoV-2 and a major factor in transmission.
· Intranasal administration of niclosamide has been demonstrated to prevent fatal outcomes in a murine challenge model
· UNI91103 is a nasal spray pump delivering a concentrated niclosamide salt solution to the nasal cavity
· UNI91103 has been tested in 44 healthy volunteers with positive results
· UNI91103 is being prepared for clinical trials in subjects at high risk of contracting COVID-19
UNION therapeutics A/S completes dosing of healthy volunteers with UNI911 (inhaled niclosamide) for COVID-19
UNION has successfully completed inhalation dosing of 44 healthy volunteers, confirming the safety and tolerability of UNI911 UNION has utilized many years of experience with niclosamide to develop UNI911, a […]
